Skip Navigation


Brain Advance Access originally published online on May 6, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
126/6/1419    most recent
awg147v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stürzebecher, S.
Right arrow Articles by McFarland, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stürzebecher, S.
Right arrow Articles by McFarland, H. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 6, 1419-1429, June 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg147

Expression profiling identifies responder and non-responder phenotypes to interferon-ß in multiple sclerosis

S. Stürzebecher1,4, K. P. Wandinger1, A. Rosenwald2, M. Sathyamoorthy2, A. Tzou1, P. Mattar1, J. A. Frank3, L. Staudt2, R. Martin1 and H. F. McFarland1

1 Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, 2 Metabolism Branch, National Cancer Institute, 3 Laboratory of Diagnostic Radiology Research, Clinical Center,National Institutes of Health, Bethesda, MD, USA, 4 SBU Therapeutics, Schering AG, Berlin, Germany

Correspondence to: Roland Martin, MD, Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B-16, 10 Center DR MSC 1400, Bethesda, MD 20892-1400, USA E-mail: martinr{at}ninds.nih.gov

Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-ß (IFN-ß, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-ß as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN-ß in relation to different disease patterns and eventually lead to optimized therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
F Sellebjerg, P Datta, J Larsen, K Rieneck, I Alsing, A Oturai, A Svejgaard, P Soelberg Sorensen, and L. Ryder
Gene expression analysis of interferon-{beta} treatment in multiple sclerosis
Multiple Sclerosis, June 1, 2008; 14(5): 615 - 621.
[Abstract] [PDF]

Home page
 Mult SclerHome page
E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel, and A. Windhagen
Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis
Multiple Sclerosis, March 1, 2008; 14(2): 166 - 176.
[Abstract] [PDF]

Home page
 StrokeHome page
A. E. Baird
Blood Genomics in Human Stroke
Stroke, February 1, 2007; 38(2): 694 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
F. R. Sharp, H. Xu, L. Lit, W. Walker, M. Apperson, D. L. Gilbert, T. A. Glauser, B. Wong, A. Hershey, D.-Z. Liu, et al.
The Future of Genomic Profiling of Neurological Diseases Using Blood
Arch Neurol, November 1, 2006; 63(11): 1529 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1
Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
T. Chtanova, R. Newton, S. M. Liu, L. Weininger, T. R. Young, D. G. Silva, F. Bertoni, A. Rinaldi, S. Chappaz, F. Sallusto, et al.
Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets
J. Immunol., December 15, 2005; 175(12): 7837 - 7847.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F Sellebjerg, C Ross, N Koch-Henriksen, P S. Sorensen, J L Frederiksen, K Bendtzen, and T L Sorensen
CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis
Multiple Sclerosis, December 1, 2005; 11(6): 641 - 645.
[Abstract] [PDF]

Home page
 BrainHome page
T. Ishizu, M. Osoegawa, F.-J. Mei, H. Kikuchi, M. Tanaka, Y. Takakura, M. Minohara, H. Murai, F. Mihara, T. Taniwaki, et al.
Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis
Brain, May 1, 2005; 128(5): 988 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
K Morgen, A L. Crawford, R D Stone, R Martin, N D Richert, J A Frank, and H F McFarland
Contrast-enhanced MRI lesions during treatment with interferon{beta}-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis, April 1, 2005; 11(2): 146 - 148.
[Abstract] [PDF]

Home page
 CirculationHome page
D. F. Moore, H. Li, N. Jeffries, V. Wright, R. A. Cooper Jr, A. Elkahloun, M. P. Gelderman, E. Zudaire, G. Blevins, H. Yu, et al.
Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke: A Pilot Investigation
Circulation, January 18, 2005; 111(2): 212 - 221.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
B. Bielekova and R. Martin
Development of biomarkers in multiple sclerosis
Brain, July 1, 2004; 127(7): 1463 - 1478.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.